PAP
FBRX icon

Persistent Asset Partners’s Forte Biosciences FBRX Stock Holding History

Persistent Asset Partners’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$175K Sell
6,744
-3,402
-34% -$98K 0.07% 207
2025
Q4 		$277K Buy
+10,146
New +$178K 0.12% 188

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Persistent Asset Partners's FBRX Position: Q1 2026 in Review

Persistent Asset Partners reduced its Forte Biosciences (FBRX) stake by 34% in Q1 2026, selling an estimated $98K and leaving 6,744 shares worth $175K. The position accounts for 0.07% of the portfolio, ranked #207.

Persistent Asset Partners first reported a position in FBRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $277K in Q4 2025. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Persistent Asset Partners held 6,744 shares of Forte Biosciences worth $175K as of Q1 2026.
  • Persistent Asset Partners sold 3,402 Forte Biosciences shares in Q1 2026, an estimated $98K.
  • Forte Biosciences made up 0.07% of Persistent Asset Partners's portfolio in Q1 2026, its #207 holding.
  • Persistent Asset Partners first reported a position in Forte Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Persistent Asset Partners's Forte Biosciences position peaked at $277K in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.